Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

Recruiting Observational Study
Thrombotic Thrombocytopenic Purpura Congenital Thrombotic Thrombocytopenic Purpura Familial Thrombotic Thrombocytopenic Purpura Thrombotic Thrombocytopenic Purpura, Congenital Upshaw-Schulman Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
450 (estimated)
Sponsor
Insel Gruppe AG, University Hospital Bern · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metallopr…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Severe ADAMTS13 deficiency ( ≤ 10% activity) and no ADAMTS 13 inhibitor on two or more occasions at least one month apart * Being a family member of a confirmed or suspected patient * Molecular analysis of ADAMTS13 gene with one or more mutations and/or positive infusion trial…
Contacts

Johanna A Kremer Hovinga, MD

+41 31 632 02 65

johanna.kremer@insel.ch

CONTACT

Marissa Schraner, Ph.D.

+41 31 632 56 90

marissa.schraner@insel.ch

CONTACT